Mkt Cap$2.17T+1.14%
24h Vol$83.64B
BTC Dom55.7%
ETH Dom8.8%
F&G15Extreme Fear
BTC$60,273.00+0.74% ETH$1,579.33+2.01% USDT$0.9985+0.00% BNB$564.43+0.82% USDC$0.9998+0.01% XRP$1.06+3.01% SOL$72.07+6.05% TRX$0.3205-0.34% FIGR_HELOC$1.03-0.48% HYPE$64.03+1.81% DOGE$0.0757+2.03% RAIN$0.0157+0.04% USDS$0.99950.00% LEO$9.35+0.99% ZEC$414.02+0.60% LAB$20.34+10.30% BTC$60,273.00+0.74% ETH$1,579.33+2.01% USDT$0.9985+0.00% BNB$564.43+0.82% USDC$0.9998+0.01% XRP$1.06+3.01% SOL$72.07+6.05% TRX$0.3205-0.34% FIGR_HELOC$1.03-0.48% HYPE$64.03+1.81% DOGE$0.0757+2.03% RAIN$0.0157+0.04% USDS$0.99950.00% LEO$9.35+0.99% ZEC$414.02+0.60% LAB$20.34+10.30%
News

VRTX

Total Stories
2
Section
VRTX
Vertex Pharmaceuticals (VRTX) Jumps Premarket on Positive Kidney Drug Trial
Market Analysis

Vertex (VRTX) Stock Climbs Premarket After Late-Stage Kidney Drug Success

Vertex Pharmaceuticals surged in premarket trading after its kidney disease drug povetacicept met the main goal in a late-stage trial.

Tim FriesMar 10, 20263 min read